Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) CFO William P. Quinn bought 40,000 shares of the business’s stock in a transaction on Monday, December 10th. The stock was purchased at an average cost of $0.47 per share, with a total value of $18,800.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
SNSS traded up $0.01 during midday trading on Wednesday, hitting $0.40. The stock had a trading volume of 487,800 shares, compared to its average volume of 216,690. The firm has a market cap of $17.18 million, a P/E ratio of -0.28 and a beta of 2.04. Sunesis Pharmaceuticals, Inc. has a 1 year low of $0.38 and a 1 year high of $7.69.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. As a group, equities research analysts anticipate that Sunesis Pharmaceuticals, Inc. will post -0.82 EPS for the current year.
Separately, Zacks Investment Research raised Sunesis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $1.50 target price for the company in a research note on Friday, November 9th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Sunesis Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $4.17.
An institutional investor recently raised its position in Sunesis Pharmaceuticals stock. Millennium Management LLC boosted its position in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 594.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,599 shares of the biopharmaceutical company’s stock after buying an additional 91,248 shares during the quarter. Millennium Management LLC owned approximately 0.31% of Sunesis Pharmaceuticals worth $290,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 44.15% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/12/12/insider-buying-sunesis-pharmaceuticals-inc-snss-cfo-acquires-40000-shares-of-stock.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Read More: What are the benefits of a balanced fund?
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.